These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 21695650)

  • 1. Phosphodiesterase inhibitors in the treatment of inflammatory diseases.
    Page CP; Spina D
    Handb Exp Pharmacol; 2011; (204):391-414. PubMed ID: 21695650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective PDE inhibitors as novel treatments for respiratory diseases.
    Page CP; Spina D
    Curr Opin Pharmacol; 2012 Jun; 12(3):275-86. PubMed ID: 22497841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.
    Dastidar SG; Rajagopal D; Ray A
    Curr Opin Investig Drugs; 2007 May; 8(5):364-72. PubMed ID: 17520865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases.
    Abbott-Banner KH; Page CP
    Basic Clin Pharmacol Toxicol; 2014 May; 114(5):365-76. PubMed ID: 24517491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential of PDE4 inhibitors in asthma or COPD.
    Spina D
    Curr Opin Investig Drugs; 2000 Oct; 1(2):204-13. PubMed ID: 11249575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphodiesterase-4 inhibitor therapy for lung diseases.
    Beghè B; Rabe KF; Fabbri LM
    Am J Respir Crit Care Med; 2013 Aug; 188(3):271-8. PubMed ID: 23656508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies.
    Giembycz MA; Newton R
    Handb Exp Pharmacol; 2011; (204):415-46. PubMed ID: 21695651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective phosphodiesterase 4 inhibitors in the treatment of allergy and inflammation.
    Smith VB; Spina D
    Curr Opin Investig Drugs; 2005 Nov; 6(11):1136-41. PubMed ID: 16312135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of a novel, orally active PDE4 inhibitor.
    Dastidar SG; Ray A; Shirumalla R; Rajagopal D; Chaudhary S; Nanda K; Sharma P; Seth MK; Balachandran S; Gupta N; Palle V
    Pharmacology; 2009; 83(5):275-86. PubMed ID: 19321962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDE4: a novel target in the treatment of chronic obstructive pulmonary disease.
    Michalski JM; Golden G; Ikari J; Rennard SI
    Clin Pharmacol Ther; 2012 Jan; 91(1):134-42. PubMed ID: 22130119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology, clinical efficacy, and tolerability of phosphodiesterase-4 inhibitors: impact of human pharmacokinetics.
    Tenor H; Hatzelmann A; Beume R; Lahu G; Zech K; Bethke TD
    Handb Exp Pharmacol; 2011; (204):85-119. PubMed ID: 21695636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the development of phosphodiesterase-4 inhibitors.
    Li G; He D; Cai X; Guan W; Zhang Y; Wu JQ; Yao H
    Eur J Med Chem; 2023 Mar; 250():115195. PubMed ID: 36809706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type 4 phosphodiesterase-dependent pathways: role in inflammatory processes.
    Jacob C; Martin-Chouly C; Lagente V
    Therapie; 2002; 57(2):163-8. PubMed ID: 12185965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease.
    Banner KH; Trevethick MA
    Trends Pharmacol Sci; 2004 Aug; 25(8):430-6. PubMed ID: 15276712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TAS-203, an oral phosphodiesterase 4 inhibitor, exerts anti-inflammatory activities in a rat airway inflammation model.
    Demizu S; Asaka N; Kawahara H; Sasaki E
    Eur J Pharmacol; 2019 Apr; 849():22-29. PubMed ID: 30716315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor.
    Nials AT; Tralau-Stewart CJ; Gascoigne MH; Ball DI; Ranshaw LE; Knowles RG
    J Pharmacol Exp Ther; 2011 Apr; 337(1):137-44. PubMed ID: 21205924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression.
    Sanz MJ; Cortijo J; Morcillo EJ
    Pharmacol Ther; 2005 Jun; 106(3):269-97. PubMed ID: 15922015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.
    Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY
    Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roflumilast for severe COPD?
    Drug Ther Bull; 2011 Apr; 49(4):45-8; quiz iii-iv. PubMed ID: 21467576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.